WO1999007720A2 - Process for the purification of acarbose, pharmaceutical composition containing same and its use for the treatment of diabetes - Google Patents
Process for the purification of acarbose, pharmaceutical composition containing same and its use for the treatment of diabetes Download PDFInfo
- Publication number
- WO1999007720A2 WO1999007720A2 PCT/IB1998/001188 IB9801188W WO9907720A2 WO 1999007720 A2 WO1999007720 A2 WO 1999007720A2 IB 9801188 W IB9801188 W IB 9801188W WO 9907720 A2 WO9907720 A2 WO 9907720A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acarbose
- process according
- cation exchanger
- acid cation
- strong acid
- Prior art date
Links
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 title claims abstract description 34
- 229960002632 acarbose Drugs 0.000 title claims abstract description 34
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000000746 purification Methods 0.000 title claims abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 150000001768 cations Chemical class 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 20
- 238000010828 elution Methods 0.000 claims abstract description 8
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 4
- 238000011068 loading method Methods 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- -1 sulfoxyethyl Chemical group 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000012461 cellulose resin Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical group CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 241000187844 Actinoplanes Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a process for the purification of pharmaceutical products, in particular for the purification of acarbose.
- Acarbose is an inhibitor of the saccharase enzyme complex of human small intestine and is used in medicaments for the treatment of diabetes.
- acarbose is 0-4 , 6-didesoxy-4- [(lS 4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl aminoglucopyranosyl-( l->4 )-D- glucopyranose .
- DE 2209832, DE 2209834 and DE 2064092 disclose the preparation of Acarbose by fermentation of Actinoplanes species.
- Dedicated purification processes are disclosed in DE 2347782 and DE 2719912, through the use of strong cation exchangers. These exchangers are gels and macro-reticular type gels, which have poor mass transfer and results in broad peaks upon elution, therefore lower purities are obtained. The purity resulting from these processes is low, around 77-88% of acarbose in the dry matter (HPLC method).
- US 4767850 and US 4666776 disclose the use of strong cation exchanger resins based on hydrophilic co-monomer and styrene co-monomer.
- EP 0226121 discloses a process for the purification of acarbose using a chromatographic column packed with a weakly acid cation exchanger which has carboxyl groups and is based on dextran or agarose or cellulose or exchangers which are derived from the former with the addition of polyacrylamide .
- the above cited patent solved the problem by using a very special weakly acid cation exchanger, having hydrophilic character and carrying out chromatographic separation in a very narrow pH range.
- an object of the present invention is a process for the purification of acarbose comprising contacting an acarbose solution with non- aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer.
- the process for the purification of acarbose essentially comprises: loading a prepurified acarbose solution in a chromatographic column packed with non-aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer; and subsequent elution.
- acarbose-enriched fractions and acarbose isolation are within the common general knowledge of the technician having ordinary skill in the art.
- prepurified acarbose is prepared by removing impurities coming out from the fermentation process. This operation is generally carried out in two steps: - adsorption: the filtered broth is brought to pH 2.5 with an acid and extracted with active charcoal to remove dark impurities, subsequently pH of the solution is raised to 7.0 with strong anion exchanger in the hydroxide form; - ion exchange: the broth, while keeping pH at 7.0 is contacted with a weak cationic exchanger to lower the conductivity of the broth.
- the characterizing part of the process of the present invention is the purification of the prepurified acarbose solution with non-aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer.
- the pH of the prepurified acarbose solution is preferably not lower than 3.0.
- the solution is then contacted with the exchanger according to the present invention and subsequently eluted with a suitable eluting medium.
- Ammonia is a preferred example of eluting medium.
- suitable eluting media are, for example, hydrochloric acid, sodium hydroxide or sodium chloride.
- the strong cation exchanger according to the present invention is prepared by washing with IN HC1 and then with water until the pH of the effluent is higher than 4.
- the non-aromatic strong acid cation exchanger which is hydrophilic and has a high mass transfer, is represented by a polymer-coated alumina matrix.
- the polymer is obtained from reactive pyridinium monomers and the functional groups are standard propyl sulfonate groups.
- Strong acid cation exchangers of this type are available on the market under the trademark BioProtocol Bio S by Cohesive Biotechnologies Inc. of Acton Massachusetts. Alternatively, other strong acid cation exchangers can be used in the process of the present invention .
- the cation exchanger consists of a sulfoxyethyl cellulose resin, for example Whatman Express-Ion Exchanger, by Whatman.
- the cation exchanger consists of a methacrylate copolymer sulfonate resin, for example Macro-Prep high S, by Bio-Rad.
- acarbose may be carried out with conventional techniques, which are well-known to the skilled person. For example, acarbose-enriched fractions can be concentrated to supersaturation, by vacuum-evaporation, then the product of interest is precipitated from a suitable medium, such as acetone.
- the purity of acarbose obtainable according to the process of the present invention is at least 98%.
- compositions containing acarbose with a content of at least 98% w/w, wherein a secondary component, which is identifiable as a sugar, is present at most in an amount of 2%, and optionally water is contained, are a within the scope of the claims .
- pharmaceutical compositions containing a therapeutically effective amount of a preparation as above described, are a further object of the present invention.
- a still further object of the present invention is the use of the above preparations for the manufacture of a medicament having inhibiting activity of - the saccharase enzyme complex of human small intestine, useful, for example, for the treatment of diabetes.
- Example 1 a) Prepurified acarbose 100 ml of a filtered cell free solution coming from the fermentation were adjusted to pH 2.5 with HNO3. The mixture was stirred for 10 minutes with 0.5 grams of active charcoal, and then centrifuged for 30 minutes at 5000 rpm. The solution was then neutralized by adding 2.5 grams of A berlite IRA 410 (OH " form). The neutral supernatant liquid was then contacted with 2.5 grams of IRC-50 to lower the conductivity.
- Example 2 100 mm length (1.7 ml volume) was packed with strong cation resin (BioProtocol Bio S) in distilled water. The column was washed with 10 ml column volumes of 0.01 N HC1 followed by 10 column volumes of distilled water at a flux of 3 ml/ in. 800 ⁇ l of the solution of prepurified acarbose, as prepared according to item a) above, were injected in the column. The column was eluted with 10 column volumes of 0.2 N NH4OH. The eluate was collected and analyzed by HPLC (as described in US 4904769) and its purity was 98% in the dry matter.
- Example 2 100 mm length (1.7 ml volume) was packed with strong cation resin (BioProtocol Bio S) in distilled water. The column was washed with 10 ml column volumes of 0.01 N HC1 followed by 10 column volumes of distilled water at a flux of 3 ml/ in. 800 ⁇ l of the solution of prepurified a
- Example 3 The method of example 1 was repeated except the strong acid cation exchanger was Whatman Sulfoethoxyethyl (SE) Cellulose Express-Ion Exchanger.
- SE Whatman Sulfoethoxyethyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The present invention discloses a process for the purification of acarbose comprising loading a prepurified acarbose solution on a chromatography column packed with a non-aromatic strong acid cation exchanger which is hydrophilic and has high mass transfer and subsequent elution.
Description
A PROCESS FOR THE PURIFICATION OF ACARBOSE.
The present invention relates to a process for the purification of pharmaceutical products, in particular for the purification of acarbose. Background of the invention Acarbose is an inhibitor of the saccharase enzyme complex of human small intestine and is used in medicaments for the treatment of diabetes.
Chemically, acarbose is 0-4 , 6-didesoxy-4- [(lS 4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2- cyclohexen-1-yl aminoglucopyranosyl-( l->4 )-D- glucopyranose .
DE 2209832, DE 2209834 and DE 2064092 disclose the preparation of Acarbose by fermentation of Actinoplanes species. Dedicated purification processes are disclosed in DE 2347782 and DE 2719912, through the use of strong cation exchangers. These exchangers are gels and macro-reticular type gels, which have poor mass transfer and results in broad peaks upon elution, therefore lower purities are obtained. The purity resulting from these processes is low, around 77-88% of acarbose in the dry matter (HPLC method).
US 4767850 and US 4666776 disclose the use of strong cation exchanger resins based on hydrophilic co-monomer and styrene co-monomer.
Strong cation exchangers of the prior art did not assure satisfactory levels of purity. Therefore, it was suggested to use a weakly acid cation exchanger.
However, in the prior art there was the opinion that it was impossible to simply substitute strongly acid
cation exchangers with weakly acid cation exchangers, because the latter can not sufficiently bind acarbose,
EP 0226121 discloses a process for the purification of acarbose using a chromatographic column packed with a weakly acid cation exchanger which has carboxyl groups and is based on dextran or agarose or cellulose or exchangers which are derived from the former with the addition of polyacrylamide . Acarbose purity not lower than 90% by weight, wherein the sugar-like secondary component is present in an amount of less than 10% by weight, but is not completely absent. Examples of up to 98% are given. The above cited patent solved the problem by using a very special weakly acid cation exchanger, having hydrophilic character and carrying out chromatographic separation in a very narrow pH range.
Use of weak cation exchangers results in higher purity material, however, it is difficult to use on a production scale because acarbose is not bound but rather slowed in elution. In addition the temperature of the exchanger must be adjusted to optimize the purification. Summary of the invention it has now surprisingly been found that a strong acid cation exchanger of a type different from the ones used till now allows the purification of acarbose on a production scale and with purities of at least 98% . Accordingly, an object of the present invention is a process for the purification of acarbose
comprising contacting an acarbose solution with non- aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer. Description of the invention The process for the purification of acarbose essentially comprises: loading a prepurified acarbose solution in a chromatographic column packed with non-aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer; and subsequent elution.
Collecting acarbose-enriched fractions and acarbose isolation are within the common general knowledge of the technician having ordinary skill in the art. To the purpose of carrying ύut the present invention, prepurified acarbose is prepared by removing impurities coming out from the fermentation process. This operation is generally carried out in two steps: - adsorption: the filtered broth is brought to pH 2.5 with an acid and extracted with active charcoal to remove dark impurities, subsequently pH of the solution is raised to 7.0 with strong anion exchanger in the hydroxide form; - ion exchange: the broth, while keeping pH at 7.0 is contacted with a weak cationic exchanger to lower the conductivity of the broth.
Suitable methods for preparing a prepurified acarbose solution are disclosed in US 4904769 and US 4767850.
The fermentation process to obtain acarbose is
disclosed in US 4062950.
The characterizing part of the process of the present invention is the purification of the prepurified acarbose solution with non-aromatic strong acid cation exchanger, which is hydrophilic and has high mass transfer.
The pH of the prepurified acarbose solution is preferably not lower than 3.0. The solution is then contacted with the exchanger according to the present invention and subsequently eluted with a suitable eluting medium.
Ammonia is a preferred example of eluting medium. Other suitable eluting media are, for example, hydrochloric acid, sodium hydroxide or sodium chloride.
The strong cation exchanger according to the present invention is prepared by washing with IN HC1 and then with water until the pH of the effluent is higher than 4. According to a first preferred embodiment of the present invention, the non-aromatic strong acid cation exchanger, which is hydrophilic and has a high mass transfer, is represented by a polymer-coated alumina matrix. The polymer is obtained from reactive pyridinium monomers and the functional groups are standard propyl sulfonate groups. Strong acid cation exchangers of this type are available on the market under the trademark BioProtocol Bio S by Cohesive Biotechnologies Inc. of Acton Massachusetts. Alternatively, other strong acid cation exchangers can be used in the process of the present
invention .
In a second preferred embodiment of the present invention, the cation exchanger consists of a sulfoxyethyl cellulose resin, for example Whatman Express-Ion Exchanger, by Whatman.
In a third preferred embodiment of the present invention, the cation exchanger consists of a methacrylate copolymer sulfonate resin, for example Macro-Prep high S, by Bio-Rad. Finally, the isolation of acarbose may be carried out with conventional techniques, which are well-known to the skilled person. For example, acarbose-enriched fractions can be concentrated to supersaturation, by vacuum-evaporation, then the product of interest is precipitated from a suitable medium, such as acetone. The purity of acarbose obtainable according to the process of the present invention is at least 98%.
The preparations obtainable by the process according to the present invention, containing acarbose with a content of at least 98% w/w, wherein a secondary component, which is identifiable as a sugar, is present at most in an amount of 2%, and optionally water is contained, are a within the scope of the claims . Analogously, pharmaceutical compositions, containing a therapeutically effective amount of a preparation as above described, are a further object of the present invention.
Pharmaceutical compositions and related preparations are disclosed in EP 0226121.
A still further object of the present invention
is the use of the above preparations for the manufacture of a medicament having inhibiting activity of - the saccharase enzyme complex of human small intestine, useful, for example, for the treatment of diabetes.
The following Examples further describe the present invention. Example 1 a) Prepurified acarbose 100 ml of a filtered cell free solution coming from the fermentation were adjusted to pH 2.5 with HNO3. The mixture was stirred for 10 minutes with 0.5 grams of active charcoal, and then centrifuged for 30 minutes at 5000 rpm. The solution was then neutralized by adding 2.5 grams of A berlite IRA 410 (OH" form). The neutral supernatant liquid was then contacted with 2.5 grams of IRC-50 to lower the conductivity.
Chromatography b) A chromatography column of 4.6 mm diameter and
100 mm length (1.7 ml volume) was packed with strong cation resin (BioProtocol Bio S) in distilled water. The column was washed with 10 ml column volumes of 0.01 N HC1 followed by 10 column volumes of distilled water at a flux of 3 ml/ in. 800 μl of the solution of prepurified acarbose, as prepared according to item a) above, were injected in the column. The column was eluted with 10 column volumes of 0.2 N NH4OH. The eluate was collected and analyzed by HPLC (as described in US 4904769) and its purity was 98%
in the dry matter. Example 2
- The method of example 1 was repeated except the strong acid cation exchanger was Whatman Sulfoethoxyethyl (SE) Cellulose Express-Ion Exchanger. Example 3
The method of example 1 was repeated except the strong acid cation exchanger was Macro-Prep high S, by Bio-Rad.
Claims
1. A process for the purification of acarbose comprising loading a prepurified acarbose solution on a chromatography column packed with a non-aromatic strong acid cation exchanger which is hydrophilic and has high mass transfer and subsequent elution.
2 A process according to claim 1, wherein said strong acid cation exchanger is based on alumina particles coated with a polymer, said polymer being obtained from reactive pyridinium monomers and bearing propyl sulfonate functional groups.
3 A process according to claim 1, wherein said strong acid cation exchanger is based on sulfoxyethyl cellulose resin.
4 A process according to claim 1, wherein said strong acid cation exchanger is based on methacrylate copoly er sulfonate. 5 A process according to anyone of claims 1-4, wherein said elution is carried out with ammonia. 6 A process according to anyone of claims 1-4, wherein said elution is carried out with sodium hydroxide . 7 A process according to anyone of claims 1-4, wherein said elution is carried out with hydrochloric acid. 8 A preparation containing acarbose with a content of not less than 98% by weight, a secondary sugar-like component at most 2%, optionally water, obtainable by the process of anyone of claims 1-7. A pharmaceutical composition containing as active ingredient an effective amount of a composition of claim 8. The use of a preparation of claim 8 for the preparation of a medicament having inhibiting activity of the saccharase enzyme complex of human small intestine. The use according to claim 10, wherein the medicament is useful for the treatment of diabetes.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU83542/98A AU8354298A (en) | 1997-08-05 | 1998-08-03 | A process for the purification of acarbose |
| EP98933857A EP1003761A2 (en) | 1997-08-05 | 1998-08-03 | A process for the purification of acarbose |
| JP2000506222A JP2001512738A (en) | 1997-08-05 | 1998-08-03 | Purification method of acabose, pharmaceutical composition containing the same, and use thereof for diabetes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI97A001880 | 1997-08-05 | ||
| IT97MI001880A IT1293819B1 (en) | 1997-08-05 | 1997-08-05 | PROCEDURE FOR THE PREPARATION OF ACARBOSE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999007720A2 true WO1999007720A2 (en) | 1999-02-18 |
| WO1999007720A3 WO1999007720A3 (en) | 1999-04-15 |
Family
ID=11377722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1998/001188 WO1999007720A2 (en) | 1997-08-05 | 1998-08-03 | Process for the purification of acarbose, pharmaceutical composition containing same and its use for the treatment of diabetes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1003761A2 (en) |
| JP (1) | JP2001512738A (en) |
| AU (1) | AU8354298A (en) |
| IT (1) | IT1293819B1 (en) |
| WO (1) | WO1999007720A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030796A1 (en) * | 1999-10-28 | 2001-05-03 | Chong Kun Dang Pharmaceutical Corp. | A process for preparing acarbose with high purity |
| WO2003014135A1 (en) * | 2001-08-07 | 2003-02-20 | Biogal Gyogyszergyar Rt | Method for purification of acarbose |
| WO2003035659A1 (en) * | 2001-10-26 | 2003-05-01 | Pliva D.D. | Acarbose purification process |
| US7253278B2 (en) * | 2003-12-02 | 2007-08-07 | Chinese Petroleum Corp | Purification process for manufacturing a high pure acarbose |
| CN102030786A (en) * | 2010-11-12 | 2011-04-27 | 丽珠集团新北江制药股份有限公司 | Preparation method of acarbose |
| CN102603822A (en) * | 2012-02-21 | 2012-07-25 | 河北华荣制药有限公司 | Method for improving purity of acarbose |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2347782C3 (en) * | 1973-09-22 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Amino sugar derivatives, processes for their preparation and medicaments containing these compounds |
| DE2719912C3 (en) * | 1977-05-04 | 1979-12-06 | Bayer Ag, 5090 Leverkusen | Process for the isolation of 0- | 4,6-dideoxy-4- [JJl SO, 4,6 / 5) -4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a - D-glucopyranosyl} - (I right arrow 4) -0- a D-glucopyranosyl- (l right arrow 4) -D-glucopyranose from culture broths |
| DE3439008A1 (en) * | 1984-10-25 | 1986-04-30 | Bayer Ag, 5090 Leverkusen | POLYMERISATES FOR CLEANING ACARBOSE |
| DE3543999A1 (en) * | 1985-12-13 | 1987-06-19 | Bayer Ag | HIGH PURITY ACARBOSE |
-
1997
- 1997-08-05 IT IT97MI001880A patent/IT1293819B1/en active IP Right Grant
-
1998
- 1998-08-03 JP JP2000506222A patent/JP2001512738A/en active Pending
- 1998-08-03 WO PCT/IB1998/001188 patent/WO1999007720A2/en not_active Application Discontinuation
- 1998-08-03 AU AU83542/98A patent/AU8354298A/en not_active Abandoned
- 1998-08-03 EP EP98933857A patent/EP1003761A2/en not_active Withdrawn
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030796A1 (en) * | 1999-10-28 | 2001-05-03 | Chong Kun Dang Pharmaceutical Corp. | A process for preparing acarbose with high purity |
| KR100383435B1 (en) * | 1999-10-28 | 2003-05-12 | 주식회사종근당 | A process for preparing acarbose with high purity |
| US6649755B1 (en) | 1999-10-28 | 2003-11-18 | Chong Kun Dang Pharmaceutical Corp. | Process for preparing acarbose with high purity |
| DE10085149B4 (en) * | 1999-10-28 | 2008-06-19 | Chong Kun Dang Pharmaceutical Corp. | Process for the production of acarbose with a high degree of purity |
| WO2003014135A1 (en) * | 2001-08-07 | 2003-02-20 | Biogal Gyogyszergyar Rt | Method for purification of acarbose |
| WO2003035659A1 (en) * | 2001-10-26 | 2003-05-01 | Pliva D.D. | Acarbose purification process |
| US6734300B2 (en) * | 2001-10-26 | 2004-05-11 | Va, Farmaceutska Industrija, Dd | Acarbose purification process |
| US7253278B2 (en) * | 2003-12-02 | 2007-08-07 | Chinese Petroleum Corp | Purification process for manufacturing a high pure acarbose |
| CN102030786A (en) * | 2010-11-12 | 2011-04-27 | 丽珠集团新北江制药股份有限公司 | Preparation method of acarbose |
| CN102603822A (en) * | 2012-02-21 | 2012-07-25 | 河北华荣制药有限公司 | Method for improving purity of acarbose |
| CN102603822B (en) * | 2012-02-21 | 2013-07-03 | 河北华荣制药有限公司 | Method for improving purity of acarbose |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001512738A (en) | 2001-08-28 |
| WO1999007720A3 (en) | 1999-04-15 |
| IT1293819B1 (en) | 1999-03-10 |
| ITMI971880A1 (en) | 1999-02-05 |
| EP1003761A2 (en) | 2000-05-31 |
| AU8354298A (en) | 1999-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1288768C (en) | Highly pure acarbose | |
| McCutchan et al. | An Improved method for the purification of tRNA by chromatography on dlhydroxyboryl substituted cellulose | |
| US4861870A (en) | Process for purifying anthracyclinone glycosides by selective adsorption on resins | |
| EP0011435A1 (en) | Method of purification of human fibroblast interferon | |
| WO1999007720A2 (en) | Process for the purification of acarbose, pharmaceutical composition containing same and its use for the treatment of diabetes | |
| US6734300B2 (en) | Acarbose purification process | |
| Lee et al. | A simple method for the preparation of polyacrylamide gels containing thioglycoside ligands | |
| CN113563394A (en) | A kind of preparation method of chitosan oligosaccharide monomer | |
| US6649755B1 (en) | Process for preparing acarbose with high purity | |
| DAHLQVIST et al. | II. Studies on Transglycosylation by Intestinal Invertase | |
| US5034064A (en) | Production process of high-purity lactulose syrup | |
| CA1082696A (en) | Separation of coformycin and its related nucleosides | |
| US3215687A (en) | Process for preparing sodium salts of ribonucleotides | |
| JPH058718B2 (en) | ||
| RU95109646A (en) | Method of preparing the highly purified monocomponent insulin | |
| WO2003014135A1 (en) | Method for purification of acarbose | |
| US20020183262A1 (en) | Method for purification of acarbose | |
| EP1309601A1 (en) | Method for purification of acarbose | |
| RU2026303C1 (en) | Method of purification of crude doxorubicin aqueous solution | |
| JPH06245786A (en) | Method for purifying colominic acid | |
| JPH0154994B2 (en) | ||
| JPS5848159B2 (en) | Purification method of urokinase | |
| JPS5834119B2 (en) | New antibiotic forteimycin D and its production method | |
| SHIGEKANE | STUDIES ON THE HETEROGENEITY OF NUCLEIC ACID IN RELATION TO SM-RESISTANCE OF AVIAN TUBERCLE BACILLI | |
| JPH0655766B2 (en) | Glucosamino oligosaccharide purification method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998933857 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09720919 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998933857 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998933857 Country of ref document: EP |